Neuronetics (STIM) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary
2 Feb, 2026Company overview and market opportunity
FDA-cleared transcranial magnetic stimulation device for depression, with 6.6 million treatments delivered to 182,000 patients.
Devices are used in nearly 1,200 centers, with about 2,300 systems in the field and reimbursement from all major payers.
Market opportunity remains large, with 4.4 million patients who have failed four drugs, and awareness of TMS has doubled to 18% in four years.
The Better Me Provider program has improved patient response times and increased business for participating practices by 61%.
Recent FDA clearance for adolescent treatment (ages 15-21) positions the company as a first-line therapy for this group.
Financial performance and guidance
Q3 revenue projected at $18.5–$19.5 million, with full-year guidance of $78–$80 million; third consecutive year of revenue growth and OpEx reduction.
Acquisition of Greenbrook TMS expected to add $74 million in revenue, with combined 2023 revenues projected at $143 million and $50 million in debt.
Cost synergies of $15 million identified, in addition to $23 million in cost reductions already achieved by Greenbrook.
New debt facility with Perceptive Advisors provides financial flexibility, with a $140 million debt conversion to stock at close.
Targeting cash flow breakeven in 2025, supported by improved cap structure and operational discipline.
Strategic rationale and integration benefits
Acquisition of Greenbrook TMS expands scale to 350 centers in 49 states, enhancing payer negotiations and reimbursement rates.
Consistent training and branding across 120 new centers expected to drive patient growth and franchise effect.
Access to Greenbrook’s call center and contracts improves practice economics and reduces reimbursement wait times.
Revenue synergies expected from expanded med management and Spravato offerings, and unified branding.
Marketing OpEx to be reduced from $21 million to $15 million without impacting customer economics.
Latest events from Neuronetics
- Q2 2026 revenue up 9.1% to $41.6M, gross margin 51.1%, net loss narrowed, liquidity risks persist.STIM
Q2 2026 - Director elections, auditor ratification, and equity plan all approved without shareholder questions.STIM
AGM 2026 - Q1 revenue up 8% to $34.5M, net loss narrows, but going concern risk remains.STIM
Q1 2026 - Votes sought for director elections, auditor ratification, compensation, and equity plan.STIM
Proxy filing - Annual meeting to vote on directors, auditor, executive pay, and new equity plan, with strong governance focus.STIM
Proxy filing - Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIM
Registration Filing - Q4 revenue up 86% YoY, 23% pro forma, with positive cash flow and 2026 growth outlook.STIM
Q4 2025 - Q3 revenue up 4% to $18.5M; Greenbrook deal approved, boosting growth and synergies.STIM
Q3 2024 - Record growth in new patient starts and adolescent market expansion set stage for 2025 breakeven.STIM
The 44th Annual William Blair Growth Stock Conference